Targeting oral anticoagulant therapy to a lower in- ternational normalized ratio (INR) (eg, 2.0 to 2.5) may be reasonable in patients with NSTE-ACS man- aged with aspirin and a P2Y12 inhibitor. (Level of Evidence: C) The combination of oral antiplatelet therapy and oral anti- coagulant therapy significantly increases the risk of bleed- ing. This risk varies widely, but on average, the addition of a single antiplatelet agent increased the risk of bleeding from a range of 2% to 3% to a range of 4% to 6%, whereas the addi- tion of DAPT to oral anticoagulant therapy ( triple therapy ) increased the risk of bleeding from a range of 4% to 6% to a range of 10% to 14%.432 435 This risk was also related to the duration of triple therapy. In patients with NSTE-ACS in whom there are indica- tions for triple therapy, the benefit of such therapy in terms of prevention of stent thrombosis, thromboembolic events, and recurrent MI must be weighed against the risk of bleeding complications. 